膜杰作
Star Staining
- Genetically modified cell lines best reflect MOA (Mechanism of Action)
- Higher activity and larger assay window for robust and reproducible cell-based bioassay
- Comprehensive application data to support assay development and validation
- Full tracible record, stringent quality control and validated cell passage stability
- Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
- Global commercial license assistance whenever regulatory filing is required
描述（Description）
The Human IL-7 R alpha/CD132 (Luc) HEK293 Reporter Cell was engineered to not only express STAT5 signaling response element, but also express the receptors full length human IL-7 R alpha (Gene ID: 3575) and CD132 (Gene ID: 3561). When stimulated with human IL-7 protein, the IL-7 R alpha/CD132 interaction drives STAT5-mediated luminescence. Neutralization of biological effect of human IL-7 protein by corresponding antibody results in a decrease in luminescence.
应用说明（Application）
• Screen for neutralizing antibodies blocking the stimulation of human IL-7 protein.
• Bioactivity detection of human IL-7 fusion protein
生长特性（Growth Properties）
Adherent
筛选标记（Selection Marker）
Puromycin (2 μg/mL) + Hygromycin (20 μg/mL)+G418(200 μg/mL)
培养基（Culture Medium）
DMEM medium + 10% FBS
冻存液（Freeze Medium）
Serum-free cell cryopreservation medium
装量（Quantity）
1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium
存储（Storage）
Frozen in liquid nitrogen.
支原体检测（Mycoplasma Testing）
Negative
无菌检测（Sterility Testing）
Negative
使用说明（Instructions for Use）
See data sheet for detailed culturing and assay protocol.
Receptor Assay
Co-expression analysis of human IL-7 R alpha and CD132 on Human IL-7 R alpha/CD132 (Luc) HEK293 Reporter Cell by FACS.
Cell surface staining was performed on Human IL-7 R alpha/CD132 (Luc) HEK293 Reporter Cell or negative control cell using FITC-labeled anti- IL-7 R alpha antibody and APC-labeled anti-CD132 antibody.
Protocol
Signaling Bioassay
Response to human IL-7 protein (RLU).
The Human IL-7 R alpha/CD132 (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human IL-7 protein (Cat. No. IL7-H4219). The EC50 was approximately 0.049 μg/mL.
Protocol
Response to human IL-7 protein (FOLD).
The Human IL-7 R alpha/CD132 (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human IL-7 protein (Cat. No. IL7-H4219). The max induction fold was approximately 283.61.
Protocol
Passage Stability
Passage stability analysis by Signaling Bioassay.
The continuously growing Human IL-7 R alpha/CD132 (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human IL-7 protein. Human IL-7 protein stimulated response demonstrates passage stabilization (fold induction and EC50) across passage 8-24.
Protocol
如有相关细胞池需求请联系我们
背景（Background）
Interleukin-7 receptor subunit alpha (IL7Ra) is also known as CD antigen CD127, which belongs to the type I cytokine receptor family and type 4 subfamily. IL7Ra /CD127 contains 1 fibronectin type-III domain. IL7Ra /CD127 is expressed on various cell types, including naive and memory T cells and many others. IL7Ra /CD127 is receptor for interleukin-7 and also acts as a receptor for thymic stromal lymphopoietin (TSLP). The IL7 receptor is a heterodimer of IL7R and IL2RG. The TSLP receptor is a heterodimer of CRLF2 and IL7R.
IL2RG/CD132 is an important signaling component of many interleukin receptors, including those of interleukin -2, -4, -7 and -21, and is thus referred to as the common gamma chain. Mutations in this gene cause X-linked severe combined immunodeficiency (XSCID) and X-linked combined immunodeficiency (XCID), a less severe immunodeficiency disorder. [provided by RefSeq, Mar 2010]
Limited Use&License Disclosure
- This cell line is provided for research use only. It is neither intended for any animal or human therapeutic use nor for any direct human in vivo use. You are restricted to share, modify, transfer, distribute, sell, sublicense, or otherwise make the cell line available for use to other researchers, laboratories, research institutions, hospitals, universities, or service organizations.
- ACROBIOSYSTEMS MAKES NO WARRANTIES OR REPRESENTATIONS OF ANY KIND, EITHER EXPRESSED OR IMPLIED, WITH RESPECT TO THE SUITABILITY OF THE CELL LINE FOR ANY PARTICULAR USE.
- ACROBIOSYSTEMS ACCEPTS NO LIABILITY IN CONNECTION WITH THE HANDLING OR USE OF THE CELL LINE.
- Modifications of the cell line, transfer to a third party, or commercial use of the cell line may require a separate license and additional fees. Please contact order.cn@acrobiosystems.com for further details.
